Clinical Trials | December 09, 2025
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
The study met its primary endpoint and all 11 secondary efficacy endpoints
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Subscribe To Our Newsletter & Stay Updated
